ASX-listed medtech (medical device) companies saw an impressive performance during Financial Year 15. In stark contrast to the market's gain of 1.2%, an equally weighted index of ASX-listed medtech stocks gained 45.6%. Canaccord believes a number of structural drivers have been responsible for this performance, and anticipates these to continue. In this report we present three companies we believe are best positioned to leverage this thematic.